Cathay Biotech Q4 Earnings Surge: Strong Biopharma Growth Drives Profits Up
Sharpened earnings show Cathay Biotech’s biopharma & bioprocessing surge, driving profit growth amid stable R&D investment and China’s flat biotech market.
2 minutes to read